CommercialCoverageMedium impact
Permanently Implanted Prostatic Devices for Benign Prostatic Hyperplasia
Blue Cross & Blue Shield of Mississippi·MS · Urology·Medical Policy
We identified it
Sep 5, 2026
Summary
This new policy classifies permanently implanted prostatic stent devices (ProVee System and Zenflow Spring Implant)—both recently FDA-approved in December 2025—as investigational for treating lower urinary tract symptoms due to benign prostatic hyperplasia. Billing teams must deny claims for these procedures as not medically necessary, except for Federal Employee Program (FEP) members where coverage may apply based on medical necessity alone.
Action Required
Immediately: Billing team must update claims processing system to deny all claims for ProVee System (CPT code to be determined upon insurance company assignment) and Zenflow Spring Implant procedures as investigational/not medically necessary. Configure system to automatically flag these claims for denial with reason code 'Investigational procedure.' Exception: Do not deny claims for FEP members; instead, route these claims for medical necessity review. Notify providers and front desk staff that patients should be informed these devices are not covered. Update denial letters to reference policy A.7.01.181. Contact provider offices to ensure they understand investigational status before scheduling procedures. Failure to implement denials will result in improper reimbursements.